- --------------------------------------------------------------------------
- --------------------------------------------------------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 1997
---------------
SEROLOGICALS CORPORATION
- --------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-26126 58-2152225
- --------------------------------------------------------------------------
(State of other (Commission file number) (IRS Employer
Jurisdiction Identification No.)
780 Park North Blvd.
Suite 110
Clarkston, Georgia 30021
- --------------------------------------------------------------------------
(Address of Principal (Zip Code)
executive offices)
Registrant's telephone number, including area code: (404) 296-5595
---------------
(Former name or former address, if changed since last report)
- --------------------------------------------------------------------------
- --------------------------------------------------------------------------
Item 5. Other Events
On August 14, 1997, Serologicals Corporation (the "Company") issued
a press release, attached hereto as Exhibit 99.1, to announce that it has
entered into an agreement to sell 950,000 shares of its common stock in a
private placement transaction. The Company also announced that one of its
stockholders had agreed to sell 250,000 shares of the Company's common stock
owned by such stockholder pursuant to the same transaction.
Item 7. Financial Statements and Exhibits
(a) Exhibits
99.1 Press Release of the Company dated August 14, 1997
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Serologicals Corporation
(Registrant)
Date: August 19, 1997 By: /s/ Russell H. Plumb//
-------------------------------
Russell H. Plumb
Vice President/Chief Financial
Officer (Principal Financial and
Accounting Officer)
EXHIBIT 99.1
NEWS
FOR IMMEDIATE RELEASE
- ---------------------
Contact: Russell H. Plumb
Chief Financial Officer
(404) 296-5595
SEROLOGICALS ANNOUNCES AGREEMENT FOR SALE
OF 950,000 SHARES OF COMMON STOCK
Atlanta, GA. (August 14, 1997) - Serologicals Corporation (Nasdaq/NM: SERO)
today announced that it has entered into an agreement for the sale of 950,000
shares of its common stock at a purchase price of $19.50 per share. Closing
of the transaction is expected later this month. The transaction also
included the sale by a selling stockholder of 250,000 shares at the same
price per share. The Company will not receive the proceeds of the sale by
such selling stockholder.
Serologicals intends to use the net proceeds of approximately $17.5
million from the shares it is selling for general corporate purposes,
including strategic acquisitions or investments.
The shares sold by the Company have not been registered under the
Securities Act of 1933, as amended, and were sold to institutional
investors pursuant to an exemption from the registration requirements of
the Securities Act. Such shares may not be offered or sold in the United
States absent registration or an applicable exemption from the registration
requirements of the Securities Act. The completion of the transaction is
contingent on, among other things, the effectiveness under the Securities
Act of a registration statement relating to the resale of such shares by
the purchasers thereof.
Serologicals Corporation, headquartered in Atlanta, is a leading
worldwide provider of specialty human antibody-based products and services
to major healthcare companies. The Company's services, including donor
recruitment, donor management and clinical testing services, enable the
Company to provide value-added products that are used as the active
ingredients in therapeutic products for the treatment and management of
medical indications such as Rh incompatibility in newborns, rabies and
hepatitis and in diagnostic products such as blood typing reagents and
diagnostic test kits.
This release may contain certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to certain risks, uncertainties and
other factors which could cause actual results to differ materially.
Additional information on factors that could potentially affect the Company
or its financial results may be found in the Company's filings with the
Securities and Exchange Commission.
